BidaskClub lowered shares of Paratek Pharmaceuticals (NASDAQ:PRTK) from a sell rating to a strong sell rating in a report issued on Friday.

PRTK has been the topic of a number of other research reports. Guggenheim set a $26.00 target price on Paratek Pharmaceuticals and gave the stock a buy rating in a report on Wednesday, October 3rd. Zacks Investment Research raised Paratek Pharmaceuticals from a sell rating to a hold rating in a report on Thursday, July 19th. ValuEngine raised Paratek Pharmaceuticals from a strong sell rating to a sell rating in a report on Tuesday, October 2nd. Cantor Fitzgerald reaffirmed a buy rating and set a $50.00 target price on shares of Paratek Pharmaceuticals in a report on Thursday, August 2nd. Finally, Wedbush set a $20.00 target price on Paratek Pharmaceuticals and gave the stock a buy rating in a report on Thursday, August 9th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company’s stock. Paratek Pharmaceuticals currently has a consensus rating of Buy and a consensus target price of $31.50.

NASDAQ:PRTK traded up $0.41 during trading hours on Friday, reaching $9.32. 781,462 shares of the stock were exchanged, compared to its average volume of 637,003. The company has a quick ratio of 7.88, a current ratio of 7.88 and a debt-to-equity ratio of 2.37. Paratek Pharmaceuticals has a 52 week low of $8.69 and a 52 week high of $24.70. The company has a market cap of $307.78 million, a PE ratio of -2.82 and a beta of 0.57.

Paratek Pharmaceuticals (NASDAQ:PRTK) last released its earnings results on Thursday, August 2nd. The specialty pharmaceutical company reported ($0.94) EPS for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.02). Paratek Pharmaceuticals had a negative return on equity of 106.39% and a negative net margin of 1,961.41%. The firm had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.10 million. As a group, sell-side analysts expect that Paratek Pharmaceuticals will post -3.41 EPS for the current fiscal year.

In other news, VP Adam Woodrow sold 8,750 shares of the stock in a transaction that occurred on Wednesday, October 3rd. The stock was sold at an average price of $9.82, for a total transaction of $85,925.00. Following the sale, the vice president now directly owns 112,917 shares in the company, valued at approximately $1,108,844.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman Michael Bigham sold 16,313 shares of the stock in a transaction that occurred on Wednesday, October 3rd. The stock was sold at an average price of $9.82, for a total value of $160,193.66. Following the sale, the chairman now owns 213,480 shares in the company, valued at $2,096,373.60. The disclosure for this sale can be found here. Insiders have sold a total of 41,503 shares of company stock worth $407,559 over the last quarter. Insiders own 6.20% of the company’s stock.

Several institutional investors have recently made changes to their positions in PRTK. Wells Fargo & Company MN raised its position in shares of Paratek Pharmaceuticals by 42.0% during the 1st quarter. Wells Fargo & Company MN now owns 27,498 shares of the specialty pharmaceutical company’s stock worth $357,000 after purchasing an additional 8,140 shares during the period. Swiss National Bank increased its position in Paratek Pharmaceuticals by 35.4% in the 1st quarter. Swiss National Bank now owns 46,700 shares of the specialty pharmaceutical company’s stock valued at $607,000 after acquiring an additional 12,200 shares during the period. Schwab Charles Investment Management Inc. increased its position in Paratek Pharmaceuticals by 39.4% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 128,746 shares of the specialty pharmaceutical company’s stock valued at $1,674,000 after acquiring an additional 36,380 shares during the period. Northern Trust Corp increased its position in Paratek Pharmaceuticals by 13.0% in the 1st quarter. Northern Trust Corp now owns 361,406 shares of the specialty pharmaceutical company’s stock valued at $4,698,000 after acquiring an additional 41,608 shares during the period. Finally, BlackRock Inc. increased its position in Paratek Pharmaceuticals by 6.6% in the 1st quarter. BlackRock Inc. now owns 2,028,845 shares of the specialty pharmaceutical company’s stock valued at $26,374,000 after acquiring an additional 125,194 shares during the period. Institutional investors and hedge funds own 77.31% of the company’s stock.

Paratek Pharmaceuticals Company Profile

Paratek Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.

See Also: Hedge Funds

Analyst Recommendations for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.